LAES vs IDAI vs XTLB vs QLYS vs VRNS

For growth investors, Varonis Systems, Inc.

(VRNS) is the stronger pick with 13. 2% revenue growth year-over-year, versus -63. 5% for SEALSQ Corp (LAES). Qualys, Inc. (QLYS) offers the better valuation at 17. 5x trailing P/E (12. 9x forward), making it the more compelling value choice. Analysts rate SEALSQ Corp (LAES) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Qualys, Inc.

is actually cheaper at 12. 9x.

Over the past 5 years, Qualys, Inc.

(QLYS) delivered a total return of -3. 1%, compared to -99. 1% for T Stamp Inc. (IDAI). Over 10 years, the gap is even starker: VRNS returned +317. 5% versus XTLB's -87. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Qualys, Inc.

(QLYS) is the lower-risk stock at 0. 53β versus SEALSQ Corp's 3. 10β — meaning LAES is approximately 484% more volatile than QLYS relative to the S&P 500. On balance sheet safety, XTL Biopharmaceuticals Ltd. (XTLB) carries a lower debt/equity ratio of 3% versus 130% for T Stamp Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Varonis Systems, Inc.

(VRNS) is pulling ahead at 13. 2% versus -63. 5% for SEALSQ Corp (LAES). On earnings-per-share growth, the picture is similar: T Stamp Inc. grew EPS 29. 3% year-over-year, compared to -223. 8% for SEALSQ Corp. Over a 3-year CAGR, QLYS leads at 11. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Qualys, Inc.

(QLYS) is the more profitable company, earning 29. 6% net margin versus -344. 1% for T Stamp Inc. — meaning it keeps 29. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: QLYS leads at 33. 2% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — QLYS leads at 82. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Qualys, Inc.

(QLYS) trades at 12. 9x forward P/E versus 242. 2x for Varonis Systems, Inc. — 229. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LAES: 145. 9% to $7. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Qualys, Inc.

(QLYS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 53), +267. 2% 10Y return). SEALSQ Corp (LAES) carries a higher beta of 3. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (QLYS: +267. 2%, LAES: -71. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (LAES (Technology) and IDAI (Technology) and XTLB (Healthcare) and QLYS (Technology) and VRNS (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: LAES is a small-cap quality compounder stock; IDAI is a small-cap quality compounder stock; XTLB is a small-cap quality compounder stock; QLYS is a small-cap deep-value stock; VRNS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.